Tempus AI (NASDAQ:TEM – Get Free Report) was upgraded by equities research analysts at Rothschild & Co Redburn to a “hold” rating in a research report issued on Tuesday, Zacks reports.
Several other research analysts also recently weighed in on the company. Freedom Capital upgraded Tempus AI to a “hold” rating in a report on Tuesday, June 30th. Stifel Nicolaus dropped their target price on Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a research note on Monday, August 3rd. Wall Street Zen raised Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Wolfe Research initiated coverage on shares of Tempus AI in a research note on Tuesday, June 2nd. They set a “peer perform” rating for the company. Finally, Weiss Ratings lowered shares of Tempus AI from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 27th. Eleven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $68.71.
View Our Latest Stock Report on Tempus AI
Tempus AI Price Performance
Tempus AI (NASDAQ:TEM – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. The business had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company’s revenue was up 21.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.22) earnings per share. Research analysts expect that Tempus AI will post -1.38 EPS for the current year.
Insider Activity at Tempus AI
In other news, CEO Eric Lefkofsky sold 11,848 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $69.87, for a total value of $827,819.76. Following the transaction, the chief executive officer directly owned 150,000 shares in the company, valued at $10,480,500. This trade represents a 7.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ryan Fukushima sold 14,286 shares of Tempus AI stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $70.00, for a total value of $1,000,020.00. Following the completion of the transaction, the chief executive officer directly owned 47,420 shares in the company, valued at $3,319,400. This represents a 23.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,043,988 shares of company stock valued at $56,963,417 over the last three months. Insiders own 24.26% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. Royal Bank of Canada lifted its stake in shares of Tempus AI by 201.2% during the first quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock worth $1,253,000 after purchasing an additional 17,359 shares in the last quarter. Rhumbline Advisers acquired a new position in Tempus AI during the 1st quarter worth $116,000. Prudential Financial Inc. acquired a new position in Tempus AI during the 2nd quarter worth $276,000. Russell Investments Group Ltd. increased its position in shares of Tempus AI by 21.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 6,527 shares of the company’s stock worth $415,000 after purchasing an additional 1,146 shares during the last quarter. Finally, Invesco Ltd. lifted its position in shares of Tempus AI by 2,926.6% during the second quarter. Invesco Ltd. now owns 211,621 shares of the company’s stock worth $13,446,000 after purchasing an additional 204,629 shares during the last quarter. Hedge funds and other institutional investors own 24.22% of the company’s stock.
About Tempus AI
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
Read More
- Five stocks we like better than Tempus AI
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
- Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.
